clinical trial · NCT04507269
Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China
Hepatitis B, ChronicVIR-2218Placebo
brief summary
This study is to evaluate the safety, pharmacokinetics characteristics, and antiviral activities of multiple doses of VIR-2218 in adults with chronic HBV infection in mainland China.
started
Aug 18, 2020
primary completion
Sep 30, 2021
completion
Sep 30, 2021
last updated
Aug 26, 2024
official title
A Phase 2 Randomized, Placebo-Controlled Study in Mainland China to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol